Cite
Vena F, Jia R, Esfandiari A, et al. MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models. Oncotarget. 2018;9(14):11592-11603doi: 10.18632/oncotarget.24294.
Vena, F., Jia, R., Esfandiari, A., Garcia-Gomez, J. J., Rodriguez-Justo, M., Ma, J., Syed, S., Crowley, L., Elenbaas, B., Goodstal, S., Hartley, J. A., & Hochhauser, D. (2018). MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models. Oncotarget, 9(14), 11592-11603. https://doi.org/10.18632/oncotarget.24294
Vena, Francesca, et al. "MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models." Oncotarget vol. 9,14 (2018): 11592-11603. doi: https://doi.org/10.18632/oncotarget.24294
Vena F, Jia R, Esfandiari A, Garcia-Gomez JJ, Rodriguez-Justo M, Ma J, Syed S, Crowley L, Elenbaas B, Goodstal S, Hartley JA, Hochhauser D. MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models. Oncotarget. 2018 Jan 22;9(14):11592-11603. doi: 10.18632/oncotarget.24294. eCollection 2018 Feb 20. PMID: 29545922; PMCID: PMC5837749.
Copy
Download .nbib